HIPRA

HIPRA is a biotech pharmaceutical company headquartered in Amer, Catalonia, Spain focused on prevention for animal and human health, with a product base of vaccines and diagnostic services.[1]

HIPRA has an international presence in 40 countries with its own subsidiaries, 3 R&D centres and production plants located in Europe (Spain) and America (Brazil).[2]

In addition, its international distribution network maintains open distribution channels with more than 100 countries, covering all 5 continents.[3]

Since 2020, the company has been developing a vaccine against COVID-19.[4]

History[edit]

HIPRA got founded in 1971, in a small laboratory in Madrid.[5] The name HIPRA comes from the surnames of its former creators: Hidalgo and Prada.

In 1991 HIPRA had a workforce of 100 people and a turnover of 10 million euros, it was an important year in HIPRA's history, with a new management team, and a redefined company expansion policy.[2]

In the year 2000, the company began internationalization, beginning the implementation of its own subsidiaries around the world.[5] Currently HIPRA has commercial subsidiaries in 40 countries. It also has 3 research centers and 6 production plants located in Europe and America.[2]

In 2009 HIPRA began to focus on prevention; therefore, it stopped investing in pharmacological products.[5]

In 2021 the new Human Health division was created by HIPRA to create new products.[6] The same year, GoodGut was acquired by HIPRA, a biotechnological start-up dedicated to the research and development of diagnostic tests for digestive diseases.[7]

Animal health[edit]

HIPRA has developed more than 100 vaccines for different animal species, both production and companion animals, against a wide variety of biological targets. In addition to its Amer plant, the company has another plant in Brazil, in the Porto Alegre conurbation. It also has a university research centre in the United States.[8]

HIPRA's animal health products include vaccines, vaccination devices,[9] integrated traceability services and diagnostic kits.

External links[edit]

References[edit]

  1. ^ https://www.hipra.com/en/discover-hipra Retrieved 2024-01-08
  2. ^ a b c https://www.hipra.com/en/history Retrieved 2024-01-08
  3. ^ "Hipra". Parc Científic de Barcelona. 2020-10-20. Retrieved 2022-11-14.
  4. ^ Limón, Raúl (2021-08-12). "First Spanish Covid-19 vaccine approved for human clinical trial". EL PAÍS English Edition. Retrieved 2021-11-05.
  5. ^ a b c "La vacuna de Hipra crea más anticuerpos que la de Pfizer como dosis de refuerzo". La Vanguardia (in Spanish). 2022-03-15. Retrieved 2022-11-15.
  6. ^ rumiNews (2020-12-14). "HIPRA da un paso firme hacia la salud humana con la vacuna frente a la Covid-19". Rumiantes el portal de rumiNews. Retrieved 2022-11-15.
  7. ^ Bosch, Imma. "Hipra compra l'empresa Goodgut - 19 ago 2021". El Punt Avui (in Catalan). Retrieved 2022-11-15.
  8. ^ "La vacuna de Hipra crea más anticuerpos que la de Pfizer como dosis de refuerzo". La Vanguardia (in Spanish). 2022-03-15. Retrieved 2022-11-18.
  9. ^ Beek, Vincent ter (2016-06-24). "Hipra takes one step forward in Smart Vaccination". Pig Progress. Retrieved 2022-11-18.